A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB) and/or an ability of ApoB to transcriptionally control vascular endothelial growth factor receptor 1 (VEGFR1).